Journal
JOURNAL OF CARDIAC FAILURE
Volume 17, Issue 4, Pages 272-281Publisher
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.cardfail.2010.11.007
Keywords
Cardiomyopathy; heart Failure; stem Cells
Categories
Ask authors/readers for more resources
Background: We investigated clinical effects of intracoronary transplantation of CD34+ cells in patients with dilated cardiomyopathy (DCM). Methods: Of 55 patients with DCM, 28 were randomized to CD34+ transplantation (SC group), and 27 patients did not receive stem cell therapy (controls). In the SC group, peripheral blood CD34+ cells were mobilized by granulocyte-colony stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and CD34+ cells were injected in the coronary artery supplying the segments with reduced viability. Results: At baseline, the 2 groups did not differ in age, gender, left ventricular ejection fraction (LVEF), or NT-proBNP levels. At I year, stem cell therapy was associated with an increase in LVEF (from 25.5 11 +/- 7.5% to 30.1 +/- 6.7%; P = .03), an increase in 6-minute walk distance (from 359 +/- 104 m to 485 +/- 127 m; P = .001), and a decrease in NT-proBNP (from 2069 +/- 1996 pg/mL to 1037 +/- 950 pg/mL; P = .01). The secondary endpoint of 1-year mortality or heart transplantation was lower in patients receiving SC therapy (2/28, 7%) than in controls (8/27, 30%) (P = .03), and SC therapy was the only independent predictor of outcome on multivariable analysis (P = .04). Conclusions: Intracoronary stem cell transplantation could lead to improved ventricular remodeling, better exercise tolerance and potentially improved survival in patients with DCM. (J Cardiac Fail 2011:17:272-281)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available